Journal
LETTERS IN APPLIED MICROBIOLOGY
Volume 71, Issue 3, Pages 229-234Publisher
OXFORD UNIV PRESS
DOI: 10.1111/lam.13334
Keywords
adjunctive therapy; anti-inflammatory; antiviral; COVID-19; microbiota; probiotics
Categories
Ask authors/readers for more resources
Understanding mechanisms of the novel SARS-CoV2 infection and progression can provide potential novel targets for prevention and/or treatment. This could be achieved via the inhibition of viral entry and/or replication, or by suppression of the immunologic response that is provoked by the infection (known as the cytokine storm). Probiotics are defined as 'live microorganisms that, when administered in adequate amounts, confer a health benefit on the host'. There is scarcity of evidence about the relationship between COVID-19 and gut microbiota. So, whether or not these supplements can prevent or ameliorate COVID-19-associated symptoms is not fully understood. The aim of this study is to provide an indirect evidence about the utility of probiotics in combating COVID-19 or its associated symptoms, through the review of its antiviral and anti-inflammatory propertiesin vitro, animal models and human trials.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available